Outcomes at 12 months in the propensity matched analysis based on type of anticoagulation (DOACs) and low molecular weight heparin) for venous thromboembolism in patients with cancer being treated with ICIs
| Outcomes . | DOAC . | Incidence rates (per 100 patient-years) . | LMWH . | Incidence rates (per 100 patient-years) . | HR (95% CI) . | P value (log-rank) . | ||
|---|---|---|---|---|---|---|---|---|
| Cases . | At risk patients . | Cases . | At risk patients . | |||||
| Primary outcome | ||||||||
| All-cause mortality | 154 | 317 | 48.6 | 214 | 317 | 67.5 | 0.73 (0.59-0.90) | .002 |
| Secondary outcomes | ||||||||
| Intracranial bleeding | 5 | 317 | 1.6 | 12 | 317 | 3.8 | 0.64 (0.25-1.63) | .347 |
| GI bleeding | 14 | 317 | 4.4 | 19 | 317 | 6.0 | 0.79 (0.40-1.57) | .498 |
| Recurrent VTE | 17 | 317 | 5.4 | 16 | 317 | 5.0 | 1.15 (0.58-2.28) | .403 |
| Recurrent PE | 12 | 317 | 3.8 | 8 | 317 | 2.5 | 1.30 (0.56-3.01) | .535 |
| Recurrent DVT | 9 | 317 | 2.8 | 9 | 317 | 2.8 | 0.93 (0.31-2.78) | .903 |
| Outcomes . | DOAC . | Incidence rates (per 100 patient-years) . | LMWH . | Incidence rates (per 100 patient-years) . | HR (95% CI) . | P value (log-rank) . | ||
|---|---|---|---|---|---|---|---|---|
| Cases . | At risk patients . | Cases . | At risk patients . | |||||
| Primary outcome | ||||||||
| All-cause mortality | 154 | 317 | 48.6 | 214 | 317 | 67.5 | 0.73 (0.59-0.90) | .002 |
| Secondary outcomes | ||||||||
| Intracranial bleeding | 5 | 317 | 1.6 | 12 | 317 | 3.8 | 0.64 (0.25-1.63) | .347 |
| GI bleeding | 14 | 317 | 4.4 | 19 | 317 | 6.0 | 0.79 (0.40-1.57) | .498 |
| Recurrent VTE | 17 | 317 | 5.4 | 16 | 317 | 5.0 | 1.15 (0.58-2.28) | .403 |
| Recurrent PE | 12 | 317 | 3.8 | 8 | 317 | 2.5 | 1.30 (0.56-3.01) | .535 |
| Recurrent DVT | 9 | 317 | 2.8 | 9 | 317 | 2.8 | 0.93 (0.31-2.78) | .903 |